Publication:
Prediction of Response to Androgen Deprivation Therapy and Castration Resistance in Primary Metastatic Prostate Cancer

dc.contributor.authorsDivrik, Rauf Taner; Turkeri, Levent; Sahin, Ali F.; Akdogan, Bulent; Ates, Ferhat; Cal, Cag; Baltaci, Sumer
dc.date.accessioned2022-03-12T18:07:36Z
dc.date.accessioned2026-01-10T18:57:48Z
dc.date.available2022-03-12T18:07:36Z
dc.date.issued2012
dc.description.abstractPurpose: We tried to establish the predictive factors influencing the initial response, as well as its duration, and time to castration resistance (CR) for primary advanced prostate cancer (PC) with bone metastasis. Methods: We evaluated all patients initially receiving androgen deprivation therapy (ADT) for primary advanced PC with bone metastasis. A total of 982 patients with complete medical records available for analysis from 18 centers were included in this study. Age, initial PSA, Gleason score (GS) and extent of bone involvement (EBI) were recorded in a database. Results: Among all the patients, 896 (91.2%) responded to ADT initially. Pretreatment PSA and EBI were significant predictors in the multivariate model. Among the 659 patients who progressed into a CR state, the mean duration of response was 22.4 months. There was a significant correlation between the CR state and nadir PSA (nPSA) level and time to nPSA. Pretreatment PSA, EBI, GS, highest tumor volume in biopsy cores (%), number of positive biopsy cores, percent positive biopsy cores and time to nPSA were proven to be significant to predict a nPSA. Pretreatment PSA, GS and EBI were statistically significant predictors of PSA normalization in multivariate analysis. The limitation of the study depends on the retrospective design and a model was developed for low standardization as a result of using multicenter data. The patients enrolled in this study were from a relatively long period of time (1989-2008). Conclusions: The results of this study indicate that it is possible to predict the initial response to ADT by pretreatment PSA levels and EBI, while the duration of response can be reflected by a multitude of clinical factors including nPSA, TTnPSA, percent positive cores, biopsy GS and EBI. Copyright (C) 2011 S. Karger AG, Basel
dc.identifier.doi10.1159/000334539
dc.identifier.issn0042-1138
dc.identifier.pubmed22179324
dc.identifier.urihttps://hdl.handle.net/11424/231039
dc.identifier.wosWOS:000299861400005
dc.language.isoeng
dc.publisherKARGER
dc.relation.ispartofUROLOGIA INTERNATIONALIS
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectProstate cancer
dc.subjectBone metastasis
dc.subjectAndrogen deprivation therapy
dc.subjectDuration of response
dc.subjectNadir PSA
dc.subjectTime to nadir PSA
dc.subjectCastration resistance
dc.subjectFUTURE-PROSPECTS
dc.subjectANTIGEN
dc.subjectSURVIVAL
dc.subjectMANAGEMENT
dc.titlePrediction of Response to Androgen Deprivation Therapy and Castration Resistance in Primary Metastatic Prostate Cancer
dc.typearticle
dspace.entity.typePublication
oaire.citation.endPage33
oaire.citation.issue1
oaire.citation.startPage25
oaire.citation.titleUROLOGIA INTERNATIONALIS
oaire.citation.volume88

Files